The present study was designed to evaluate the potential role of bradykinin antagonists (R-715; bradykinin B-1 receptor antagonist and icatibant; bradykinin B-2 receptor antagonist) in treatment of allergic airway inflammation in comparison to dexamethasone and montelukast. R-715 as dexamethasone significantly decreased peribronchial leukocyte infiltration, bronchoalveolar lavage fluid (BALF) albumin and interleukin 1 beta as well as serum OVA-specific IgE level. Also, R-715 like montelukast significantly decreased BALF cell count (total and eosinophils). Icatibant showed negative results. The current findings suggest that selective bradykinin B-1 receptor antagonists may have the therapeutic potential for the treatment of allergic airway inflammation. (C) 2016 Elsevier B.V. All rights reserved.